article thumbnail

The trends driving ELRIG Drug Discovery 2022

Drug Discovery World

This year’s event will cover some of the most exciting advancements in areas spanning screening, automation, high content imaging, disease models, cell and gene therapies and how innovation is being driven through partnerships and collaborations. Cell and gene therapies. billion, compared to $19.9

article thumbnail

Epigenetic Editing with CRISPR Might Be Easier Than We Thought

XTalks

The tool could also prove to be safer than conventional CRISPR-based gene therapies as it does not involve DNA editing, and thus would not cause potentially harmful off-target genomic changes. Nearly one third of human genes lack CGIs, which would limit the use of the tool.

DNA 98
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Using CRISPR to Edit the Epigenome Might Be Easier Than We Thought

XTalks

The tool could also prove to be safer than conventional CRISPR-based gene therapies as it does not involve DNA editing, and thus would not cause potentially harmful off-target genomic changes. Nearly one third of human genes lack CGIs, which would limit the use of the tool.

DNA 52
article thumbnail

The use of base editing in stem-cell based therapies

Drug Discovery World

This precision editing approach allows for a host of potential therapeutic applications, including gene silencing, either via splice site disruption or the addition of premature stop codons, as well as gene correction in single nucleotide variant diseases. References 1:Thomson J, Itskovitz-Eldor J, Shapiro S, et al.